Real is Crude
Capture high-quality low potency leads for more successful drug discovery
In contrast to high-throughput screening, which relies on vast libraries of small molecules, fragment-based drug discovery takes a different approach to identify potential starting molecules for drug development. Using libraries typically comprising just a few thousand molecules, each of <20 heavy (non-hydrogen) atoms, fragment-based drug discovery identifies hits with varying affinity for the drug target. The hit-molecules can subsequently be merged, linked, or expanded to transform weak binders and fragments with moderate binding affinity into high-affinity small molecules. A major advantage of this method is that it promises higher hit rates compared to traditional small molecule screening, since the lower molecular complexity of fragments corresponds to fewer unfavorable interactions with the drug target.
Despite being driven by recent developments in screening technologies, fragment-based drug discovery remains challenging. This is mainly due to the small size of the fragment molecules, the limited quantities of material available, and the molecular stability.
Separate binders from non-binders
The Creoptix™ WAVEsystem provides a reliable environment for fragment-based drug discovery and small molecule screening, allowing for accurate off-rate kinetic analysis of crude reaction mixtures. With exquisite sensitivity, the ability to resolve extremely rapid dissociating kinetics, and innate compatibility with the high molecular weight ratios characteristic of most drug discovery programs, the Creoptix™ WAVEsystem improves fragment-based screening and kinetic analysis of small molecules to accelerate drug development.
Traditional approaches to fragment-based drug discovery rank molecules by affinity rather than kinetics. This is because fragment libraries often contain a high proportion of weak binders with very fast off-rates that cannot be resolved by standard instrumentation. Since affinity describes the relationship between the on-rate and the off-rate, it does not discriminate between a hit and a non-specific binding event. Moreover, due to the weak binding and often low purities, the signal obtained from fragments may be mistaken for affinity when no actual binding has occurred. Measuring affinity can therefore extend workflows by generating large numbers of false positive results.
Kinetic trajectory as lead matter progresses from hits to drugs, adapted from "Application of label-free biosensing in drug discovery: The past, present and future", CH Drug Discovery Chemistry, April 22nd 2016 by John Quinn.
Accurately measure fast off-rate kinetics of weakly binding fragments
Using the Creoptix™ WAVEsystem, researchers can reliably determine off-rates of up to 10s-1, starting with just a crude reaction mixture. By adopting this approach, the occurrence of false positives is minimized. Moreover, since the off-rate is not concentration dependent, only very small amounts of material are required to generate a comprehensive data set, making the Creoptix™ WAVEsystem ideal for fragment-based screening. A further advantage of the WAVEsystem is that it provides high sensitivity at even very low immobilization levels, significantly reducing the costs associated with obtaining purified target protein.
Compatible with crude reaction mixtures
Save time by removing the need for fragment purification.
Eliminate false positives
Measure off-rates rather than affinity for accurate identification of hits, resolve off-rates of up to 10 s-1.
More than buffer
Experiment with non-traditional solvents, including high percentages of acetonitrile and DMSO, thanks to our robust microfluidic technology.
Analysis of small molecule binding kinetics complements fragment-based drug discovery
Historically, hit compounds have been identified from libraries of small molecules by high throughput screening. This usually involves running the libraries through an assay designed to analyze the impact of each molecule on one or more downstream readouts, an approach that can be extremely costly and time-consuming and that can generate false positive results. A further drawback of many high throughput screens is that they frequently offer only limited sensitivity, especially at large target-to-analyte molecular weight ratios, meaning that low-potency small molecules are frequently overlooked.
By using the Creoptix™ WAVEsystem to perform real-time kinetic analysis of small molecule binding to drug targets, researchers can gain valuable insight to more effectively guide the optimization and progression of promising drug candidates. Employing our proprietary Grating-Coupled Interferometry (GCI) technology to deliver superior sensitivity over traditional Surface Plasmon Resonance (SPR) technologies, the Creoptix™ WAVEsystem pushes the limits of what is possible to overcome mass-transport limitations. This is achievable within a broad range of immobilization levels, meaning that it is no longer necessary to saturate the surface with the drug target.
Used in combination with fragment-based screening approaches, kinetic analysis of small molecule binding to drug targets has considerable potential to expedite drug discovery programs. Chemical engineering based on structural insights from the fragment-based screen allows researchers to develop small molecules that are more likely to deliver the specificity and potency necessary to achieve the desired therapeutic outcome.
No clogging, regardless of size
Take advantage of the Creoptix™ WAVEsystem’s valveless microfluidics to analyze and characterize larger molecules.
Push the limits and generate high-quality binding kinetics with our sensitive GCI technology and resolve data at very low responses
Small molecules can’t hide any more
Analyze interactions between small molecules and large drug targets with confidence (target-to-analyte molecular weight ratios up to >1000:1)